Elkhorn Investments LLC purchased a new stake in shares of Stryker Co. (NYSE:SYK) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 8,180 shares of the medical technology company’s stock, valued at approximately $1,199,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. San Francisco Sentry Investment Group CA boosted its stake in Stryker by 47.8% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares in the last quarter. Advisor Partners LLC boosted its stake in shares of Stryker by 7.2% during the 4th quarter. Advisor Partners LLC now owns 4,827 shares of the medical technology company’s stock worth $779,000 after acquiring an additional 326 shares in the last quarter. Putnam FL Investment Management Co. boosted its stake in shares of Stryker by 0.7% during the 4th quarter. Putnam FL Investment Management Co. now owns 44,867 shares of the medical technology company’s stock worth $6,947,000 after acquiring an additional 332 shares in the last quarter. Founders Capital Management LLC boosted its stake in shares of Stryker by 1.4% during the 4th quarter. Founders Capital Management LLC now owns 25,790 shares of the medical technology company’s stock worth $3,993,000 after acquiring an additional 350 shares in the last quarter. Finally, LS Investment Advisors LLC boosted its stake in shares of Stryker by 3.6% during the 4th quarter. LS Investment Advisors LLC now owns 10,249 shares of the medical technology company’s stock worth $1,587,000 after acquiring an additional 354 shares in the last quarter. 75.71% of the stock is owned by hedge funds and other institutional investors.
Stryker Co. (SYK) traded down $0.20 on Wednesday, hitting $166.91. The stock had a trading volume of 53,508 shares, compared to its average volume of 1,360,802. The stock has a market capitalization of $62,898.64, a price-to-earnings ratio of 62.35, a P/E/G ratio of 2.41 and a beta of 0.70. Stryker Co. has a one year low of $129.82 and a one year high of $170.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 annualized dividend and a dividend yield of 1.13%. Stryker’s dividend payout ratio is 70.15%.
In related news, insider Graham A. Mclean sold 2,984 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $160.53, for a total transaction of $479,021.52. Following the completion of the sale, the insider now directly owns 9,100 shares in the company, valued at $1,460,823. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP William E. Berry, Jr. sold 1,306 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total value of $214,732.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,611 shares of company stock valued at $7,178,719. 7.40% of the stock is owned by corporate insiders.
Several equities research analysts have recently weighed in on SYK shares. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $161.00 to $173.00 in a research note on Thursday, November 16th. SunTrust Banks reissued a “buy” rating and set a $161.00 price objective on shares of Stryker in a research note on Friday, November 17th. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research note on Thursday, December 7th. Finally, BMO Capital Markets raised Stryker to a “market perform” rating and set a $163.00 price objective for the company in a research note on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Stryker currently has an average rating of “Buy” and a consensus price target of $163.85.
ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/03/14/elkhorn-investments-llc-takes-1-20-million-position-in-stryker-co-syk.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.